IGM Biosciences, Inc. (IGMS) Latest Stock News & Headlines
Get the latest IGM Biosciences, Inc. (IGMS) stock news and headlines to help you in your trading and investing decisions.
Top 1% Biotech, IGM Biosciences, Plummets On Scrapped Drug, …
Oct 1, 2024 · IGM Biosciences (IGMS) is developing imvotamab as a treatment for rheumatoid arthritis and systemic lupus erythematosus. In the shift, IGM is winding down efforts to develop aplitabart, a...
Bay Area biotech firm IGM Biosciences, once worth billions, guts …
An IGM news release from Jan. 9 shed more light on the layoffs. The company’s phase 1b studies of its imvotamab antibody for arthritis and lupus flopped; CEO Dr. Mary Beth Harler wrote that ...
IGM Biosciences, Inc. (IGMS) Stock Price, News, Quote & History
Find the latest IGM Biosciences, Inc. (IGMS) stock quote, history, news and other vital information to help you with your stock trading and investing.
IGM Biosciences Shares Drop 68% as Company Halts Key …
Jan 10, 2025 · Citing unsatisfactory outcomes in early trials and starting a major personnel reduction as part of its strategy realignment, IGM Biosciences (IGMS, Financials) said it is stopping development...
Sanofi shrinks $6B biobucks deal with IGM - Fierce Biotech
Apr 17, 2024 · Sanofi is shrinking a collaboration with IGM Biosciences by half, shedding three cancer targets to focus on three immunology and inflammation targets.
IGM Biosciences Provides Strategic Update on Autoimmunity …
MOUNTAIN VIEW, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company committed to developing and delivering medicines to treat patients with autoimmune and inflammatory diseases, today announced a strategic update to halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific ...
IGM Biosciences Halts Development Of Imvotamab, IGM-2644; …
Jan 9, 2025 · (RTTNews) - Biotechnology company IGM Biosciences, Inc. (IGMS), Thursday announced a strategic update to halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T...
IGM Biosciences Halts Key Drug Programs, Cuts 73% of …
Jan 9, 2025 · IGM Biosciences (IGMS) announced the discontinuation of two key pipeline programs: imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) for autoimmune diseases. The decision comes after interim data from Phase 1b studies showed insufficient B cell depletion in rheumatoid arthritis and systemic lupus erythematosus patients.
Home - IGM Biosciences
Jan 9, 2025 · IGM Biosciences is pioneering a new class of antibody medicines for the treatment of autoimmune and inflammatory diseases. Building upon the greater binding power provided by the naturally occurring IgM antibody structure, as compared with the commonly used IgG antibody structure, IGM has been able to create “super antibodies” with the ...
- Some results have been removed